121 related articles for article (PubMed ID: 38142382)
1. Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma.
Jung EK; Chu TH; Kim SA; Vo MC; Nguyen VT; Lee KH; Jung SH; Yoon M; Cho D; Lee JJ; Yoon TM
Cytotherapy; 2024 Mar; 26(3):242-251. PubMed ID: 38142382
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer.
Jung EK; Chu TH; Vo MC; Nguyen HPQ; Lee DH; Lee JK; Lim SC; Jung SH; Yoon TM; Yoon MS; Cho D; Lee JJ; Cho HH
Cytotherapy; 2022 Sep; 24(9):905-915. PubMed ID: 35778350
[TBL] [Abstract][Full Text] [Related]
3. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Crist M; Yaniv B; Palackdharry S; Lehn MA; Medvedovic M; Stone T; Gulati S; Karivedu V; Borchers M; Fuhrman B; Crago A; Curry J; Martinez-Outschoorn U; Takiar V; Wise-Draper TM
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328378
[TBL] [Abstract][Full Text] [Related]
4. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
Wang H; Nan S; Wang Y; Xu C
J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
6. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
[TBL] [Abstract][Full Text] [Related]
9. Impaired intratumoral natural killer cell function in head and neck carcinoma.
Mele D; Pessino G; Trisolini G; Luchena A; Benazzo M; Morbini P; Mantovani S; Oliviero B; Mondelli MU; Varchetta S
Front Immunol; 2022; 13():997806. PubMed ID: 36341402
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of HLA-B-associated transcript 3 impairs the tumoricidal effect of natural killer cells through promoting the T cell immunoglobulin and mucin domain-containing-3 signaling in a mouse head and neck squamous cell carcinoma model.
Yang J; Xiang J; Zhu M; Zhao Y; Zhou L; Hu B; Wang C
Immunobiology; 2022 Jan; 227(1):152127. PubMed ID: 34968777
[TBL] [Abstract][Full Text] [Related]
11. Landscape of natural killer cell activity in head and neck squamous cell carcinoma.
Charap AJ; Enokida T; Brody R; Sfakianos J; Miles B; Bhardwaj N; Horowitz A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428584
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
13. High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor.
Wang F; Zhang G; Xu T; Ma J; Wang J; Liu S; Tang Y; Jin S; Li J; Xing N
J Exp Clin Cancer Res; 2024 Jan; 43(1):24. PubMed ID: 38245792
[TBL] [Abstract][Full Text] [Related]
14. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model.
Thangaraj JL; Ahn SY; Jung SH; Vo MC; Chu TH; Thi Phan MT; Kwon M; Lee KH; Kim M; Song GY; Yang DH; Ahn JS; Kim HJ; Cho D; Lee JJ
Cell Mol Immunol; 2021 Jul; 18(7):1652-1661. PubMed ID: 33980993
[TBL] [Abstract][Full Text] [Related]
15. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma.
Guy JB; Espenel S; Louati S; Gauthier A; Garcia MA; Vial N; Malésys C; Ardail D; Alphonse G; Wozny AS; Rodriguez-Lafrasse C; Magné N
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1905-1916. PubMed ID: 33791846
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.
Tam K; Schoppy DW; Shin JH; Tay JK; Moreno-Nieves U; Mundy DC; Sunwoo JB
Otolaryngol Head Neck Surg; 2018 Jul; 159(1):76-84. PubMed ID: 29436278
[TBL] [Abstract][Full Text] [Related]
17. Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer.
Yang F; Yuan C; Chen F; Qin ZS; Schmitt NC; Lesinski GB; Saba NF; Teng Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):76. PubMed ID: 38468260
[TBL] [Abstract][Full Text] [Related]
18. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.
Kundu K; Ghosh S; Sarkar R; Edri A; Brusilovsky M; Gershoni-Yahalom O; Yossef R; Shemesh A; Soria JC; Lazar V; Joshua BZ; Campbell KS; Elkabets M; Porgador A
Cancer Immunol Res; 2019 Jul; 7(7):1120-1134. PubMed ID: 31164357
[TBL] [Abstract][Full Text] [Related]
20. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
